RCKT stock forecast
Our latest prediction for Rocket Pharmaceuticals, Inc.'s stock price was made on the Dec. 10, 2019 when the stock price was at 24.23$.
In the short term (2weeks), RCKT's stock price should underperform the market by -5.42%. During that period the price should oscillate between -13.13% and +13.18%.
In the medium term (3months), RCKT's stock price should underperform the market by -10.77%. During that period the price should oscillate between -38.31% and +22.35%.Get email alerts
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.86$ per share.
The book value per share is 3.96$
Three months stock forecastDec. 10, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|